Allied Market Research
Loading...
0
New
New

Heparin Market by Product (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), and Ultra-Low Molecular Weight Heparin (ULMWH)), Application (Venous Thromboembolism, Coronary Artery Disease, Atrial Fibrillation, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2028

A06186
Pages: 221
May 2021 | 2332 Views
   
Author(s) : Sushant Terdale, Monika Darandale , Onkar Sumant
Tables: 112
Charts: 41
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Heparin Market

Request Now !

Heparin Market Overview:

The global heparin market size was valued at $6,535 million in 2020, and is projected to reach $11,015 million by 2028, registering a CAGR of 6.6% from 2021 to 2028.

Heparin Market is expected witness modest growth during this pandemic period owing to the usage of low molecular weight heparin during COVID-19 treatment.

Heparin, also known as unfractionated heparin (UFH), is a glycosaminoglycan that occurs naturally. It is used as an anticoagulant in medicine (blood thinner). It is particularly useful for the treatment of heart attacks and unstable angina. It is injected into a vein or injected under the skin. It is used to treat a variety of health problems, such as acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during cardiac surgery. Its use also extends to the administration of major orthopedic procedures such as hip and knee replacements.

Heparin-Market

Get more information on this report : Request Sample Pages

The increase in prevalence of venous thrombosis and cardiovascular diseases is the key factor that drives the growth of the global heparin market. In addition, application of heparin in various surgeries, such as orthopedic and heart surgeries, and rise in number of patients undergoing such surgeries further boost the growth of the heparin market. Moreover, the availability of synthetic and semi-synthetic heparin mimetics that help treat cancer, coagulation, and inflammatory diseases is expected to provide lucrative opportunities for heparin adoption. In addition, increased government support for healthcare infrastructure improvements and comprehensive R&D activities to grow heparin with enhanced therapeutic potential and minimum side effects further drive the growth of the heparin market. However, many adverse side-effects associated with heparin and presence of other anticoagulant in the market may hamper the growth of the heparin market.

The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has also been a positive effect and surge in demand for various medical services, including heparin. During the COVID-19 pandemic, a large number of patients are suffering from coronavirus, which is linked to respiratory diseases. As a result, the demand for heparin has increased as it helps to control respiratory inflation and thin the blood of those at risk of a blood clot. Low molecular weight heparins are anticoagulant medications that are well tolerated and have few side effects. Regardless of risk ratings, all patients admitted to the hospital with (suspected) COVID-19 are treated with prophylactic-dose low-molecular-weight heparin. A baseline chest CT is performed on patients who have COVID-19 symptoms and are anticipated to be admitted to the hospital. The study of the binding of LMWH with SARS-CoV-2 Spike protein could lead to the development of an effective therapeutic approach to reduce pulmonary embolism and thrombosis complications in SARS-CoV-2 patients. As a result, LMWH used in the treatment of COVID-19 patients and clinical study & development continue in these pandemic times to improve LMWH's efficacy.

Heparin Market Segmentation

The global heparin market is segmented into product, application, distribution channel, and region. On the basis of product, the market is categorized into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). By application, it is classified into venous thromboembolism, atrial fibrillation, coronary artery disease, and others. By distribution channel, it is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

Based on product, the low molecular weight heparin segment currently dominates the global market and is expected to continue during the forecast period. Longer and more predictable operation than UFH and easy self-administration at home by subcutaneous injection, which decreases or eliminates hospital stays, and no requirement of daily blood monitoring are all important factors that boost the heparin market growth.

Heparin Market
By Product

Your browser does not support the canvas element.

Low molecular weight heparin segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Based on distribution channel, the hospital pharmacies segment accounted for majority of the market revenue in 2020 and is expected to maintain its dominance during the forecast period as patients' trust in hospitals is based on high-quality services and easy access to medications as well as greater reliance on healthcare professionals for heparin prescriptions.

Heparin Market
By Distribution Channel

Your browser does not support the canvas element.

Hospital Pharmacies segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of the Asia-Pacific Heparin Market  

Asia-Pacific is expected to exhibit the fastest growth rate during the forecast period, owing to constantly expanding healthcare infrastructure, presence of untapped resources, economic development, and increasing initiatives by private & public organizations, which are projected to drive the growth of the heparin market in emerging countries in Asia-Pacific. In addition, larger patient pool for cardiovascular diseases and an increase in the aging population are some factors, which drive the growth of the market. Moreover, increase in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the heparin market in the region.

Heparin Market
By Region

2028
Europe 
North America
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 7.8 % during 2021-2028.

Get more information on this report : Request Sample Pages

The key market players profiled in the report include Baxter International Inc., B. Braun Holding GmbH & Co. KG, Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co KGaA, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Leo Pharma A/S, Pfizer Inc., Sanofi S.A, Teva Pharmaceuticals, and Viatris Inc.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global heparin market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the heparin market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing heparin market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of heparin used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments

By Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-low Molecular Weight Heparin (ULMWH)

By Application

  • Venous Thromboembolism
  • Coronary Artery Disease
  • Atrial Fibrillation    
  • Others     

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA  
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020

3.5Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in incidence of venous thromboembolism and cardiovascular disorders
3.5.1.2.Rise in geriatric population
3.5.1.3.Increase in usage of heparin in surgical procedures

3.5.2.Restraints

3.5.2.1.Side effects associated with heparin
3.5.2.2.Presence of alternative anticoagulants

3.5.3.Opportunities

3.5.3.1.Availability of synthetic and semi-synthetic heparin mimetics
3.5.3.2.R&D activities to develop heparin with improved therapeutic 

3.5.4.Impact analysis

3.6Covid-19 Impact analysis on heparin market

CHAPTER 4:HEPARIN MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Unfractionated Heparin

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Low Molecular Weight Heparin (LMWH)

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Ultra-low Molecular Weight Heparin (ULMWH)

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:HEPARIN MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Venous Thromboembolism

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Coronary Artery Disease

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.Atrial Fibrillation

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast
5.5.2.Market analysis, by country

CHAPTER 6:HEPARIN MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospital Pharmacies

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Drug stores and retail pharmacies

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Online pharmacies

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:HEPARIN MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. heparin market, by product
7.2.2.1.2.U.S. heparin market, by application
7.2.2.1.3.U.S. heparin market, by distribution channel

7.2.2.2.Canada

7.2.2.2.1.Canada heparin market, by product
7.2.2.2.2.Canada heparin market, by application
7.2.2.2.3.Canada heparin market, by distribution channel

7.2.2.3.Mexico

7.2.2.3.1.Mexico heparin market, by product
7.2.2.3.2.Mexico heparin market, by application
7.2.2.3.3.Mexico heparin market, by distribution channel

7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by distribution channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany heparin market, by product
7.3.2.1.2.Germany heparin market, by application
7.3.2.1.3.Germany heparin market, by distribution channel

7.3.2.2.France

7.3.2.2.1.France heparin market, by product
7.3.2.2.2.France heparin market, by application
7.3.2.2.3.France heparin market, by distribution channel

7.3.2.3.UK

7.3.2.3.1.UK heparin market, by product
7.3.2.3.2.UK heparin market, by application
7.3.2.3.3.UK heparin market, by distribution channel

7.3.2.4.Italy

7.3.2.4.1.Italy heparin market, by product
7.3.2.4.2.Italy heparin market, by application
7.3.2.4.3.Italy heparin market, by distribution channel

7.3.2.5.Spain

7.3.2.5.1.Spain heparin market, by product
7.3.2.5.2.Spain heparin market, by application
7.3.2.5.3.Spain heparin market, by distribution channel

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe heparin market, by product
7.3.2.6.2.Rest of Europe heparin market, by application
7.3.2.6.3.Rest of Europe heparin market, by distribution channel

7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by distribution channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan heparin market, by product
7.4.2.1.2.Japan heparin market, by application
7.4.2.1.3.Japan heparin market, by distribution channel

7.4.2.2.China

7.4.2.2.1.China heparin market, by product
7.4.2.2.2.China heparin market, by application
7.4.2.2.3.China heparin market, by distribution channel

7.4.2.3.India

7.4.2.3.1.India heparin market, by product
7.4.2.3.2.India heparin market, by application
7.4.2.3.3.India heparin market, by distribution channel

7.4.2.4.Australia

7.4.2.4.1.Australia heparin market, by product
7.4.2.4.2.Australia heparin market, by application
7.4.2.4.3.Australia heparin market, by distribution channel

7.4.2.5.Rest of Asia-Pacific

7.4.2.5.1.Rest of Asia-Pacific heparin market, by product
7.4.2.5.2.Rest of Asia-Pacific heparin market, by application
7.4.2.5.3.Rest of Asia-Pacific heparin market, by distribution channel

7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by distribution channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil heparin market, by product
7.5.2.1.2.Brazil heparin market, by application
7.5.2.1.3.Brazil heparin market, by distribution channel

7.5.2.2.South Africa

7.5.2.2.1.South Africa heparin market, by product
7.5.2.2.2.South Africa heparin market, by application
7.5.2.2.3.South Africa heparin market, by distribution channel

7.5.2.3.Saudi Arabia

7.5.2.3.1.Saudi Arabia heparin market, by product
7.5.2.3.2.Saudi Arabia heparin market, by application
7.5.2.3.3.Saudi Arabia heparin market, by distribution channel

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA heparin market, by product
7.5.2.4.2.Rest of LAMEA heparin market, by application
7.5.2.4.3.Rest of LAMEA heparin market, by distribution channel
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.Baxter International Inc.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segment
8.1.4.Product portfolio
8.1.5.Business performance

8.2.B. Braun Holding GmbH & Co. KG

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Business performance

8.3.Dr. Reddy’s Laboratories Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.3.5.Business performance

8.4.Fresenius SE & Co KGaA

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segment
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segment
8.5.4.Product portfolio

8.6.Leo Pharma A/S

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.Pfizer Inc.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.Sanofi S.A.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.Teva Pharmaceuticals

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance

8.10.Viatris Inc.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Operating business segments
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.HEPARIN MARKET, BY PRODUCT, 2020-2028 ($MILLION)
TABLE 02.UNFRACTIONATED HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 03.LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 04.ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 05.HEPARIN MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 06.VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 07.CORONARY ARTERY DISEASE HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 08.ATRIAL FIBRILLATION HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 09.OTHERS HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 10.HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 11.HOSPITAL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 12.DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 13.ONLINE PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 14.HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 15.NORTH AMERICA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 16.U.S. HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 17.U.S. HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 18.U.S. HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 19.CANADA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 20.CANADA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 21.CANADA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 22.MEXICO HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 23.MEXICO HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 24.MEXICO HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 25.NORTH AMERICA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 26.NORTH AMERICA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 27.NORTH AMERICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 28.EUROPE HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 29.GERMANY HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 30.GERMANY HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 31.GERMANY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 32.FRANCE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 33.FRANCE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 34.FRANCE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 35.UK HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 36.UK HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 37.UK HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 38.ITALY HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 39.ITALY HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 40.ITALY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 41.SPAIN HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 42.SPAIN HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 43.SPAIN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 44.REST OF EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 45.REST OF EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 46.REST OF EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 47.EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 48.EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 49.EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 50.ASIA-PACIFIC HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 51.JAPAN HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 52.JAPAN HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 53.JAPAN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 54.CHINA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 55.CHINA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 56.CHINA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 57.INDIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 58.INDIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 59.INDIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 60.AUSTRALIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 61.AUSTRALIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 62.AUSTRALIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 63.REST OF ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 64.REST OF ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 65.REST OF ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 66.ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 67.ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 68.ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 69.LAMEA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 70.BRAZIL HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 71.BRAZIL HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 72.BRAZIL HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 73.SOUTH AFRICA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 74.SOUTH AFRICA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 75.SOUTH AFRICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 76.SAUDI ARABIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 77.SAUDI ARABIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 78.SAUDI ARABIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 79.REST OF LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 80.REST OF LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 81.REST OF LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 82.LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 83.LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 84.LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 85.BAXTER: COMPANY SNAPSHOT
TABLE 86.BAXTER: OPERATING SEGMENTS
TABLE 87.BAXTER: PRODUCT PORTFOLIO
TABLE 88.B. BRAUN: COMPANY SNAPSHOT
TABLE 89.B. BRAUN: OPERATING SEGMENTS
TABLE 90.B.BRAUN: PRODUCT PORTFOLIO
TABLE 91.DR. REDDY’S LAB: COMPANY SNAPSHOT
TABLE 92.DR. REDDY’S LAB: OPERATING SEGMENTS
TABLE 93.DR. REDDY’S LAB: PRODUCT PORTFOLIO
TABLE 94.FRESENIUS: COMPANY SNAPSHOT
TABLE 95.FRESENIUS: OPERATING SEGMENTS
TABLE 96.FRESENIUS: PRODUCT PORTFOLIO
TABLE 97.HEBEI: COMPANY SNAPSHOT
TABLE 98.FRESENIUS: OPERATING SEGMENTS
TABLE 99.HEBEI: PRODUCT PORTFOLIO
TABLE 100.LEO: COMPANY SNAPSHOT
TABLE 101.LEO: OPERATING SEGMENTS
TABLE 102.IBM: PRODUCT PORTFOLIO
TABLE 103.PFIZER: COMPANY SNAPSHOT
TABLE 104.PFIZER: OPERATING SEGMENTS
TABLE 105.PFIZER: PRODUCT PORTFOLIO
TABLE 106.SANOFI: COMPANY SNAPSHOT
TABLE 107.SANOFI: OPERATING SEGMENTS
TABLE 108.SANOFI: PRODUCT PORTFOLIO
TABLE 109.ASPEN: COMPANY SNAPSHOT
TABLE 110.TEVA: PRODUCT PORTFOLIO
TABLE 111.VIATRIS: COMPANY SNAPSHOT
TABLE 112.VIATRIS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL HEPARIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.HIGH THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF UNFRACTIONATED HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CORONARY ARTERY DISEASE HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF ATRIAL FIBRILLATION HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF OTHERS HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 18.BAXTER: REVENUE, 2018–2020 ($MILLION)
FIGURE 19.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.BAXTER: REVENUE SHARE BY REGION 2020 (%)
FIGURE 21.B BRAUN: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.B BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.B BRAUN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 24.DR. REDDY’S LAB: REVENUE, 2018–2020 ($MILLION)
FIGURE 25.DR. REDDY’S LAB: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.DR. REDDY’S LAB: REVENUE SHARE BY REGION 2020 (%)
FIGURE 27.FRESENIUS: REVENUE, 2018–2020 ($MILLION)
FIGURE 28.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.FRESENIUS: REVENUE SHARE BY REGION 2020 (%)
FIGURE 30.LEO: REVENUE, 2018–2020 ($MILLION)
FIGURE 31.LEO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.LEO: REVENUE SHARE BY REGION 2020 (%)
FIGURE 33.PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 34.PFIZER: REVENUE SHARE BY REGION 2020 (%)
FIGURE 35.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 36.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.TEVA.: REVENUE, 2018–2020 ($MILLION)
FIGURE 39.TEVA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.VIATRIS: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)

 
 

Heparin is an anticoagulant (blood thinner) that prevents blood clots from forming. It is a medication that is used to treat and prevent blood clots caused by certain medical conditions or procedures. It is also used to reduce the risk of blood clots prior to surgery. Moreover, it is used clinically in cardiac surgeries, dialysis, and deep vein thrombosis. 

Furthermore, increase in cases of patients suffering from coronary heart disease and myocardial infection, rise in prevalence of venous thromboembolism and cardiovascular disorders, increase in number of patients undergoing such surgeries, and growth of geriatric population are expected to drive the growth of the heparin market. Furthermore, high healthcare expenditures and patient awareness boost the market growth. However, the adverse side-effects associated with heparin, such as heparin-induced thrombocytopenia, are expected to hinder the growth of the market.  

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Heparin market is $6,534.90 million in 2020.

A. The forcast period for Heparin market is 2021 to 2028

A. The market value of Heparin market in 2021 is $7,025.02 million.

A. The base year is 2020 in Enteral Nutrition market

A. Top companies such as Sanofi S.A., Pfizer Inc., B. Braun Holding GmbH & Co. KG , Fresenius SE & Co KGaA, Viatris Inc., Baxter International Inc., and Dr. Reddy’s Laboratories Ltd held a high market position in 2020.

A. Low molecular weight heparin segment is the most influencing segment owing to longer and more predicable activity than UFH and rise in demand for low molecular weight heparin products in hospitalized patients suffering from venous thromboembolism.

A. Increase in cases of patients suffering from coronary heart disease and myocardial infection, rise in prevalence of venous thromboembolism and cardiovascular disorders, increase in number of patients undergoing such surgeries, and growth of geriatric population drive the growth of the heparin market.

A. Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing to growing geriatric population and the rising prevalence of long-term survivors of acute myocardial infarction (AMI).

A. Heparin is an anticoagulant (blood thinner) that prevents blood clots from forming.

A. Heparin products are used to treat and prevent blood clots caused by certain medical conditions or procedures. It is also used to reduce the risk of blood clots prior to surgery and used clinically in cardiac surgeries, dialysis, and deep vein thrombosis.

Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Heparin Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers